It is also unlikely that tumour inhibition after depletion was due to low numbers of remaining CD4+ or CD8+ specific T-cells, since depletion was >97% initially for both subsets, and 70–80% three weeks after the last mAb injection. The gene discussed is CD4; the disease is neoplasm.